<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585843</url>
  </required_header>
  <id_info>
    <org_study_id>AAAO9102</org_study_id>
    <nct_id>NCT02585843</nct_id>
  </id_info>
  <brief_title>Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance</brief_title>
  <official_title>Pilot Study of Natriuretic Versus Standard Doses of Mineralocorticoid Receptor Antagonists in Heart Failure and Loop Diuretic Resistance in Outpatients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-center, double-blind and randomized placebo controlled trial
      for evaluation of a 7-day 100mg daily dose of spironolactone on weight loss and resolution of
      signs and symptoms of congestion in outpatients with acute decompensated heart failure
      (ADHF). Patients who are not responding to their current loop diuretics will be considered
      for this study. Mineralocorticoid receptor antagonists (MRAs) are recommended as standard of
      care in management of heart failure (HF) patients. However, recommended doses of MRAs
      (spironolactone 25mg/daily or eplerenone 50mg/daily) will not have any impact on signs and
      symptoms of volume overload. Therefore, the proposed study will aim to show the impact of
      this outpatient regimen to improve diuresis and possible reduction in hospitalization for
      further diuretic management in HF patients with signs and symptoms of congestion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence and prevalence of heart failure (HF) is rising with more than 5 million
      Americans suffering from this syndrome. Hospitalization rates for acute decompensated heart
      failure (ADHF) are also remarkably high, exceeding more than 1 million admissions per year.
      Congestion is the main cause of hospitalization for ADHF. Loop diuretics as the main therapy
      for decongestion, often are not adequate since many patients with ADHF develop &quot;loop diuretic
      resistance&quot;. These patients will require hospitalization for intravenous diuretic or other
      advanced decongestion therapies. Thus, novel decongestion therapies are needed to decrease
      hospital admission rates and subsequent complications of multiple hospitalizations.
      Hyperaldosteronism, not only is a pivotal pathogenic factor in HF, but also contributes to
      loop diuretic resistance. Attempts for normalization of circulatory aldosterone with
      mineralocorticoid receptor antagonists (MRAs), mainly spironolactone, have shown to decrease
      mortality in HF patients with reduced left ventricular ejection fraction (LVEF). Moreover,
      MRAs significantly decrease the rate of rehospitalization in both HF with preserved and
      reduced LVEF. The dose of spironolactone in these trials is 25mg daily. However, this dose
      does not increase natriuresis (urinary sodium excretion). Natriuresis is achieved with higher
      doses of MRAs. Therefore, the primary aim of this study is to examine the efficacy of 7-day
      100mg daily of spironolactone on weight loss and resolution of signs and symptoms of
      congestion in patients aged 60 years with ADHF and loop diuretic resistance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">March 31, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>7 days</time_frame>
    <description>change in body weight measured in kilograms between weight at baseline and weight at 7 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated Jugular Venous Pressure (cmH2O)</measure>
    <time_frame>7 days</time_frame>
    <description>Change in estimated jugular venous pressure by physical exam in cmH2O between baseline and 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute Walk Test Distance (6MWT)</measure>
    <time_frame>7 days</time_frame>
    <description>At baseline and final visit. The 6MWT will be conducted per American Thoracic Society guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score on the Visual Analogue Scale (VAS)</measure>
    <time_frame>7 days</time_frame>
    <description>Dyspnea will be assessed at baseline and at 7 days with the score on the visual analogue scale (VAS). The scores range from 0 (minimum) to 100 (maximum) with higher numbers representing improvements in dyspnea (i.e. better) and lower numbers representing worsening of dyspnea (i.e. worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 7 on the Seven-Level Likert Scale</measure>
    <time_frame>7 days</time_frame>
    <description>Dyspnea will be assessed using a Seven-Level Likert Scale at baseline and the day 7 visit. The outcome measure will be reported as a difference between these two assessments (value at 7 days minus the value at baseline). The values on this scale range from 1 to 7 with higher numbers indicating overall better subjective assessment related to the symptom of dyspnea. Therefore, positive numbers represent an overall improvement in dyspnea during the study intervention and the higher (more positive) this difference is, the better the subject's relief of dyspnea at the conclusion of the study intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>High-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone 100mg</intervention_name>
    <description>2 capsules of study medication consist of 100mg, PO (oral) for 7 days</description>
    <arm_group_label>High-dose</arm_group_label>
    <other_name>Aldactone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone 25mg</intervention_name>
    <description>25mg/day of spironolactone</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Aldactone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of heart failure with either reduced or preserved ejection fraction for 3
             months

          -  Patients with New York Heart Association (NYHA) class II- IV heart failure symptoms,
             with at least one worsening symptom (Dyspnea on exertion, shortness of breath,
             orthopnea, early satiety) and one sign of congestion (pulmonary rales, elevated
             jugular venous pressure10cmHg, peripheral edema and ascites)

          -  Decision by primary cardiologist or heart failure (HF) specialist to increase the home
             diuretic dose

          -  Stable treatment with beta-blockers for 1 month unless contraindicated (i.e.
             intolerance, bradycardia) as specified by primary cardiologist/HF provider

          -  Stable treatment with angiotensin converting enzyme-1 (ACE-1) or angiotensin receptor
             blocker (ARB) for 1 month

          -  Spironolactone dose 25mg or eplerenone 50mg per day

          -  Daily furosemide or furosemide equivalent dose of 80mg or greater

          -  Serum potassium concentration 4.5 mmol/L or 5.0 mmol/L if on potassium supplements

          -  Estimated Glomerular Filtration Rate (eGFR) by Modification of Diet in Renal Disease
             (MDRD) equation 40 ml/min/1.73

        Exclusion Criteria:

          -  Inability to complete informed consent form

          -  Allergy or intolerance to spironolactone

          -  Systolic blood pressure &lt;100 mmHg

          -  Patient in need of hospitalization per cardiologist decision

          -  Current inotrope dependency

          -  Current mechanical circulatory support

          -  Acute coronary syndromes or unstable angina within the past 4 weeks

          -  History of cardiac transplant

          -  Obstructive cardiac valvular disease

          -  Primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy

          -  Significant ventricular arrhythmia necessitating defibrillator therapy within the past
             14 days

          -  Atrioventricular conduction abnormality greater than first-degree block

          -  Primary liver disease resulted in cirrhosis or abnormal liver function tests
             (transaminases and alkaline phosphatase levels 3 times the upper limit of normal

          -  Acute malignancy

          -  Active infection requiring antimicrobial treatment (Suppression antimicrobial for
             chronic infections are exempt)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur R Garan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <results_first_submitted>February 2, 2019</results_first_submitted>
  <results_first_submitted_qc>June 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2019</results_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Arthur R. Garan</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine at the Columbia University Medic, Dept of Medicine Cardiology</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Mineralocorticoid receptor antagonists</keyword>
  <keyword>Loop diuretic resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT02585843/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT02585843/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High-dose</title>
          <description>Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
Spironolactone 100mg: 2 capsules of study medication consist of 100mg, PO (oral) for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care</title>
          <description>Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
Spironolactone 25mg: 25mg/day of spironolactone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High-dose</title>
          <description>Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
Spironolactone 100mg: 2 capsules of study medication consist of 100mg, PO (oral) for 7 days</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
Spironolactone 25mg: 25mg/day of spironolactone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="9"/>
                    <measurement group_id="B2" value="63.5" spread="15"/>
                    <measurement group_id="B3" value="62.6" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline 6 minute walk test</title>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177" spread="78"/>
                    <measurement group_id="B2" value="196" spread="68"/>
                    <measurement group_id="B3" value="187" spread="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Body Weight</title>
        <description>change in body weight measured in kilograms between weight at baseline and weight at 7 days</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-dose</title>
            <description>Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
Spironolactone 100mg: 2 capsules of study medication consist of 100mg, PO (oral) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
Spironolactone 25mg: 25mg/day of spironolactone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>change in body weight measured in kilograms between weight at baseline and weight at 7 days</description>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="2.0"/>
                    <measurement group_id="O2" value="-1.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estimated Jugular Venous Pressure (cmH2O)</title>
        <description>Change in estimated jugular venous pressure by physical exam in cmH2O between baseline and 7 days</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-dose</title>
            <description>Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
Spironolactone 100mg: 2 capsules of study medication consist of 100mg, PO (oral) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
Spironolactone 25mg: 25mg/day of spironolactone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estimated Jugular Venous Pressure (cmH2O)</title>
          <description>Change in estimated jugular venous pressure by physical exam in cmH2O between baseline and 7 days</description>
          <units>cmH2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="2.5"/>
                    <measurement group_id="O2" value="-3.9" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 6-minute Walk Test Distance (6MWT)</title>
        <description>At baseline and final visit. The 6MWT will be conducted per American Thoracic Society guidelines.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-dose</title>
            <description>Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
Spironolactone 100mg: 2 capsules of study medication consist of 100mg, PO (oral) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
Spironolactone 25mg: 25mg/day of spironolactone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6-minute Walk Test Distance (6MWT)</title>
          <description>At baseline and final visit. The 6MWT will be conducted per American Thoracic Society guidelines.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="46"/>
                    <measurement group_id="O2" value="36" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score on the Visual Analogue Scale (VAS)</title>
        <description>Dyspnea will be assessed at baseline and at 7 days with the score on the visual analogue scale (VAS). The scores range from 0 (minimum) to 100 (maximum) with higher numbers representing improvements in dyspnea (i.e. better) and lower numbers representing worsening of dyspnea (i.e. worse).</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-dose</title>
            <description>Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
Spironolactone 100mg: 2 capsules of study medication consist of 100mg, PO (oral) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
Spironolactone 25mg: 25mg/day of spironolactone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score on the Visual Analogue Scale (VAS)</title>
          <description>Dyspnea will be assessed at baseline and at 7 days with the score on the visual analogue scale (VAS). The scores range from 0 (minimum) to 100 (maximum) with higher numbers representing improvements in dyspnea (i.e. better) and lower numbers representing worsening of dyspnea (i.e. worse).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="34"/>
                    <measurement group_id="O2" value="25" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 7 on the Seven-Level Likert Scale</title>
        <description>Dyspnea will be assessed using a Seven-Level Likert Scale at baseline and the day 7 visit. The outcome measure will be reported as a difference between these two assessments (value at 7 days minus the value at baseline). The values on this scale range from 1 to 7 with higher numbers indicating overall better subjective assessment related to the symptom of dyspnea. Therefore, positive numbers represent an overall improvement in dyspnea during the study intervention and the higher (more positive) this difference is, the better the subject's relief of dyspnea at the conclusion of the study intervention.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-dose</title>
            <description>Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
Spironolactone 100mg: 2 capsules of study medication consist of 100mg, PO (oral) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
Spironolactone 25mg: 25mg/day of spironolactone</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 7 on the Seven-Level Likert Scale</title>
          <description>Dyspnea will be assessed using a Seven-Level Likert Scale at baseline and the day 7 visit. The outcome measure will be reported as a difference between these two assessments (value at 7 days minus the value at baseline). The values on this scale range from 1 to 7 with higher numbers indicating overall better subjective assessment related to the symptom of dyspnea. Therefore, positive numbers represent an overall improvement in dyspnea during the study intervention and the higher (more positive) this difference is, the better the subject's relief of dyspnea at the conclusion of the study intervention.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.9"/>
                    <measurement group_id="O2" value="2.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High-dose</title>
          <description>Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
Spironolactone 100mg: 2 capsules of study medication consist of 100mg, PO (oral) for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care</title>
          <description>Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
Spironolactone 25mg: 25mg/day of spironolactone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>A. Reshad Garan</name_or_title>
      <organization>Columbia University</organization>
      <phone>(917) 374-3346</phone>
      <email>arg2024@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

